MicroBlate™ Flex begins lung tumour clinical study

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces the first patient treated in a new post-market multi-centre "ablate and resect" clinical study (the "Study") evaluating the safety and performance of its MicroBlate™ Flex for the treatment of lung tumours.

In the Study, patients who are scheduled for lung tumour resection first undergo ablation with Creo's MicroBlate™ Flex device. Once surgically removed, the tumour is analysed to assess device performance against the patient's pre and post-procedural scans, a vital performance measure only achievable from this study design. The Study is taking place at the Amsterdam University Medical Centre in the Netherlands and at the Royal Brompton Hospital in the UK.

Full details of the Study can be found here: https://clinicaltrials.gov/study/NCT06689488

The Study complements Creo's previously announced post-market study designed to gather immediate safety and longer-term follow-up clinical data. These studies, in conjunction with the post-market programme underway with Intuitive which delivers robotically-guided lung tumour ablation using Creo's MicroBlate™ Flex alongside Intuitive's Ion endoluminal system, will provide a substantial and robust clinical dataset ahead of commercialisation.

About MicroBlate™ Flex

MicroBlate™ Flex is a soft tissue ablation device, designed to ablate nodules and tumours in several tissue types. Lung tumour ablation is a potential critical application for MicroBlate™ Flex. Lung cancer is the most common cancer in men and the second most common cancer in women. Treatment options are currently sub optimal and typically involve chemotherapy, radiation therapy, surgery or a combination thereof. The unique design of MicroBlate™ Flex offers patients the prospect of a significantly less invasive outcome when treating lung tumours.

Commenting, Craig Gulliford, Chief Executive Officer, said:

"We're delighted to see the start of an additional clinical study to generate data on MicroBlate™ Flex, which we believe has the potential to become an invaluable tool for treating early lung cancers or metastatic tumours in the lung, whilst minimising damage to health parts of the lung. Our collaboration with Intuitive further strengthens our emerging position at the forefront of minimally invasive lung cancer treatment and highlights the broad potential of MicroBlate™ Flex as we move toward commercialisation."